United Therapeutics Chairperson & CEO Exercises and Sells $5.1M in Stock via 10b5-1 Plan
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Insider Transaction: United Therapeutics Corp (UTHR)
**Insider**: Martine A. Rothblatt (Chairperson & CEO)
**Date**: 2026-10-05
**Type**: Option Exercise & Sale (Rule 10b5-1 Plan)
### Transaction Summary
- **Shares Exercised**: 9,500 @ $117.76
- **Shares Sold**: 9,500 @ ~$541.64 avg
- **Gross Proceeds**: ~$5,145,537
- **Net Profit Spread**: ~$4,026,817
- **Shares Retained (This Trust)**: 324,443 shares
- **Total Beneficial Ownership Remaining**: Over 668,000 common shares + 299,910 options
Comprehensive Analysis
Executive Summary
On October 5, 2026, Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), executed an option exercise and sale of 9,500 shares of common stock at a weighted average sale price of approximately $541.64 per share, generating aggregate gross proceeds of approximately $5.15 million.
Key Transaction Details
- Option Exercise: Exercised 9,500 stock options expiring on March 15, 2027, with an exercise strike price of $117.76 per share (total cost: $1,118,720).
- Open Market Sales: Sold all 9,500 resulting shares across 11 tranches ranging in weighted average prices from $536.26 to $546.63, yielding gross proceeds of $5,145,537 and a pre-tax gain of approximately $4.03 million.
- Pre-Arranged 10b5-1 Plan: The transaction was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan continues until the earlier of exercising 1,734,410 stock options or December 31, 2026.
Post-Transaction Holdings
Following this transaction, Dr. Rothblatt continues to hold substantial equity in United Therapeutics:
- Indirect Ownership via Selling Trust: 324,443 common shares
- Direct Ownership: 40,513 common shares
- Other Indirect Trusts/Spouse: 303,772 common shares
- Derivative Holdings (Selling Trust): 299,910 remaining stock options
Market & Governance Impact
Because these transactions were carried out in accordance with an established Rule 10b5-1 trading plan and involve options approaching expiration, they represent routine executive equity compensation management rather than discretionary market timing. The trading significance is assessed as Low.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.